Literature DB >> 10610624

Guanylyl cyclase C messenger RNA is a biomarker for recurrent stage II colorectal cancer.

B Cagir1, A Gelmann, J Park, T Fava, A Tankelevitch, E W Bittner, E J Weaver, J P Palazzo, D Weinberg, R D Fry, S A Waldman.   

Abstract

BACKGROUND: Patients with stage II colorectal cancer and no histologic evidence of lymph node invasion develop recurrent disease, presumably because of undetected micrometastases. Guanylyl cyclase C is expressed by intestinal and colorectal cancer cells but not by extraintestinal tissues or tumors.
OBJECTIVE: To examine the expression of guanylyl cyclase C messenger RNA (mRNA) in lymph nodes of patients with node-negative colorectal cancer who did and did not have recurrent disease.
DESIGN: Case-control study.
SETTING: Tertiary care academic medical center. PATIENTS: Paraffin-embedded lymph nodes were obtained from 21 patients with histologically confirmed node-negative colorectal cancer who had undergone resection. Controls included 11 patients without disease recurrence 6 or more years after resection, and case-patients included 10 patients whose disease recurred up to 3 years after resection. MEASUREMENTS: Sections of paraffin-embedded lymph nodes were obtained from each patient and were pooled, and their RNA was analyzed by reverse transcriptase polymerase chain reaction (RT-PCR).
RESULTS: Guanylyl cyclase C mRNA was expressed in lymph nodes from all patients with recurrent disease but not in those from patients without recurrent disease (P = 0.004). Nested RT-PCR that used primers for carcinoembryonic antigen, a marker for colorectal cancer, identified carcinoembryonic antigen mRNA in lymph nodes from only 1 of 10 patients with recurrent disease and those from 0 of 11 patients without recurrent disease. The odds ratio for death associated with expression of guanylyl cyclase C mRNA in regional lymph nodes was 15.0 (95% CI, 1.1 to 756.7).
CONCLUSIONS: Expression of guanylyl cyclase C mRNA in lymph nodes is associated with recurrence of colorectal cancer in patients with stage II disease. Analysis of guanylyl cyclase mRNA expression by RT-PCR may be useful for colorectal cancer staging.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10610624     DOI: 10.7326/0003-4819-131-11-199912070-00002

Source DB:  PubMed          Journal:  Ann Intern Med        ISSN: 0003-4819            Impact factor:   25.391


  44 in total

1.  Molecular staging estimates occult tumor burden in colorectal cancer.

Authors:  Alex Mejia; Stephanie Schulz; Terry Hyslop; David S Weinberg; Scott A Waldman
Journal:  Adv Clin Chem       Date:  2010       Impact factor: 5.394

2.  Guanylyl cyclase C agonists regulate progression through the cell cycle of human colon carcinoma cells.

Authors:  G M Pitari; M D Di Guglielmo; J Park; S Schulz; S A Waldman
Journal:  Proc Natl Acad Sci U S A       Date:  2001-07-03       Impact factor: 11.205

Review 3.  Progress in the development of prognostic and predictive markers for gastrointestinal malignancies.

Authors:  Crystal S Denlinger; Steven J Cohen
Journal:  Curr Treat Options Oncol       Date:  2007-10

4.  Occult tumor burden contributes to racial disparities in stage-specific colorectal cancer outcomes.

Authors:  Terry Hyslop; David S Weinberg; Stephanie Schulz; Alan Barkun; Scott A Waldman
Journal:  Cancer       Date:  2011-09-01       Impact factor: 6.860

Review 5.  Molecular staging individualizing cancer management.

Authors:  Alex Mejia; Stephanie Schulz; Terry Hyslop; David S Weinberg; Scott A Waldman
Journal:  J Surg Oncol       Date:  2012-04-01       Impact factor: 3.454

Review 6.  Guanylyl cyclase C as a biomarker in colorectal cancer.

Authors:  Terry Hyslop; Scott A Waldman
Journal:  Biomark Med       Date:  2013-02       Impact factor: 2.851

Review 7.  Immunotherapeutic strategies to target prognostic and predictive markers of cancer.

Authors:  Michael S Magee; Adam E Snook; Glen P Marszalowicz; Scott A Waldman
Journal:  Biomark Med       Date:  2013-02       Impact factor: 2.851

Review 8.  GCC signaling in colorectal cancer: Is colorectal cancer a paracrine deficiency syndrome?

Authors:  P Li; J E Lin; G P Marszlowicz; M A Valentino; C Chang; S Schulz; G M Pitari; Scott A Waldman
Journal:  Drug News Perspect       Date:  2009 Jul-Aug

9.  Previstage GCC test for staging patients with colorectal cancer.

Authors:  Alex Mejia; Scott A Waldmana
Journal:  Expert Rev Mol Diagn       Date:  2008-09       Impact factor: 5.225

10.  CpG-island methylation of the ER promoter in colorectal cancer: analysis of micrometastases in lymph nodes from UICC stage I and II patients.

Authors:  J Harder; V Engelstaedter; H Usadel; S Lassmann; M Werner; P Baier; F Otto; M Varbanova; E Schaeffner; M Olschewski; H E Blum; O G Opitz
Journal:  Br J Cancer       Date:  2009-01-13       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.